|
業務類別
|
Biotechnology |
|
業務概覽
|
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failureassociated liver disease (IFALD). |
| 公司地址
| 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010 |
| 電話號碼
| +1 646 844-0337 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.protaratx.com |
| 員工數量
| 33 |
| Mr. Leonardo Viana Nicacio, M.D. |
Chief Medical Officer |
-- |
25/04/2025 |
| Ms. Jacqueline Zummo, M.B.A.,M.P.H.,PhD |
Chief Research & Development Officer |
美元 475.76K |
10/03/2026 |
| Mr. Jesse Shefferman, PhD |
Chief Executive Officer, President and Director |
美元 632.34K |
10/03/2026 |
| Ms. Hannah Fry |
Vice President, Controller and Principal Accounting Officer |
-- |
10/03/2026 |
| Mr. Patrick Fabbio |
Chief Financial Officer |
美元 464.97K |
10/03/2026 |
|
|
| Dr. Richard S. Levy,M.D. |
Independent Director |
10/03/2026 |
| Mr. Jesse Shefferman, PhD |
Chief Executive Officer, President and Director |
10/03/2026 |
| Dr. Jane Huang, M.D. |
Independent Director |
10/03/2026 |
| Mr. Barry P. Flannelly, Pharm.D. |
Independent Director |
10/03/2026 |
| Ms. Cynthia Smith |
Independent Director |
10/03/2026 |
| Dr. Roger J. Garceau,M.D.,F.A.A.P. |
Independent Director |
10/03/2026 |
| Dr. Michael Edward Solomon, PhD |
Independent Director |
10/03/2026 |
| Mr. Luke M. Beshar |
Chairman of the Board |
10/03/2026 |
| Mr. Gregory P. Sargen |
Independent Director |
10/03/2026 |
|
|
|
|
